May 26, 2020 8:33am
Regenerative Medicine Earnings listing for Q1/20
My focus is to define the net income or loss, the per share amounts commonly an LPS (loss-per-share), cash positions (EOQ – “end-of-quarter”) and the “runway” of continuing operations.
Schedule for the LPS (loss-per-share) earnings of Q1/2020 of my 35 covered companies:
Coming this week on 5/28:
Adverum Biotechnologies (ADVM)
Mesoblast (MESO)
35 companies, 1 interpreter!
Insight, foresight and recommendation
3 hours 29 min ago
RegMed Investors’ (RMi) pre-open: It’s “make” a buck day!
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors
© 2024 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.